LAG3 and lung cancer: In addition, the use of well-established immune checkpoint inhibitors, such as PD-1/PD-L1 blockers or LAG-3 antagonists, may hold enhanced therapeutic relevance in lung cancer patients exposed to high levels of air pollution.